Journal
CLINICAL CANCER RESEARCH
Volume 12, Issue 24, Pages 7279-7283Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-06-1589
Keywords
-
Categories
Funding
- NCI NIH HHS [CA 75681, R01 CA075681, R01 CA075681-10] Funding Source: Medline
Ask authors/readers for more resources
Maspin (mammary serine protease inhibitor) was identified in 1994 by subtractive hybridization analysis of normal mammary tissue and breast cancer cell lines. Subsequently emerging evidence portrays maspin as a multifaceted protein, interacting with diverse group of intercellular and extracellular proteins, regulating cell adhesion motility apoptosis and angiogenesis and critically involved mammary gland development. The tissue-specific expression of maspin is epigenetically controlled and aberrant methylation of maspin promoter is closely associated with maspin gene silencing identification of new tissue sites expressing maspin and novel maspin-binding partners has expanded the horizon for maspin research and promises maspin-based therapeutic approaches for combating cancer. This perspective briefly outlines the past and present strides in deciphering this unique molecule and speculates on new frontiers in maspin research and prospects of maspin as a diagnostic/prognostic indicator in cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available